CIK 0001840229
- Non-accelerated filer
- Smaller reporting company
- Emerging growth company
MiNK Therapeutics, Inc.
Sign in to watch- Ticker
- INKT
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- Phone
- +1 212-994-8250
- Business address
- 149 FIFTH AVENUE, SUITE 500, NEW YORK, NY, 10010
- Former names
- AgenTus Therapeutics, Inc., AgenTus Therapeutics, Inc.
- 4 Grant or award Director acquired 21,802 shares (grant or award)
- 4 Grant or award Director acquired 15,454 shares (grant or award)
- 4 Grant or award Director acquired 17,841 shares (grant or award)
- 4 Grant or award Director acquired 15,077 shares (grant or award)
- 4 Grant or award Director acquired 17,967 shares (grant or award)
- 4 Grant or award Director acquired 16,185 shares (grant or award)
- 4 Grant or award Director acquired 18,685 shares (grant or award)
- 4 Grant or award Director acquired 15,790 shares (grant or award)
- 4 Grant or award Director acquired 18,816 shares (grant or award)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Grant or award Director acquired 17,068 shares (grant or award)
- 4 Grant or award Director acquired 17,188 shares (grant or award)
- 4 Grant or award Director acquired 14,424 shares (grant or award)
- 4 Grant or award Director acquired 14,784 shares (grant or award)
- 4 Open-market buy 10% owner bought 22,975 shares at an average $1.10 ($25,270)
- 4 Other disposition Chief Executive Officer disposed of 695,750 shares (other)
- 4 Open-market buy 10% owner bought 15,001 shares at $1.09 ($16,380)
- 4 Shares withheld for taxes Chief Executive Officer gave up 148,550 shares (to pay taxes)
- 4 Exercise or conversion Chief Executive Officer acquired 695,750 shares (option exercise)
Page 4 of 8 · 145 filings